AbCellera reports Q3 2026 results, highlights ABCL635 Phase 2 and $200M raiseNov 9Quarterly updateAbCellera Biologics Inc.
AbCellera completes pricing of $200 million offering, files final prospectus supplementAug 13FinancingAbCellera Biologics Inc.
AbCellera reports positive Phase 2 results for menopause drug ABCL635Aug 10Clinical readoutAbCellera Biologics Inc.
AbCellera to lead T-cell engager discovery for Vertex under new autoimmune disease pactJul 29PartnershipAbCellera Biologics Inc.